Floatz logo

plb1004

Non-Small-Cell Lung Cancer

Beijing Pearl Biotechnology Limited Liability CompanyPhase 3Active
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
89/ 100

Competitive context

1205 Active assets in the Non-Small-Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB

View all 50 →

Same molecule, other indications

plb1004 is also rated in:

lung cancerDormant
CC
Indicative ·
47 / 100
View asset →
MET AlterationDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →